Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Curated Information Page
PubMed Id: 16239300 
Denley A, et al. (2006) Differential activation of insulin receptor isoforms by insulin-like growth factors is determined by the C domain. Endocrinology 147, 1029-36 16239300
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download Sites

Y999-p - INSR (human)
Modsite: YASSNPEyLSASDVF SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y999‑p, INSR iso2 (human): Y987‑p, INSR (mouse): Y989‑p, INSR (rat): Y1000‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-2 increase
IGF-1 no change compared to control

Y1011-p - INSR (human)
Modsite: DVFPCSVyVPDEWEV SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1011‑p, INSR iso2 (human): Y999‑p, INSR (mouse): Y1001‑p, INSR (rat): Y1012‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-2 increase
IGF-1 no change compared to control

Y1185-p - INSR (human)
Modsite: FGMTRDIyETDYYRK SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1185‑p, INSR iso2 (human): Y1173‑p, INSR (mouse): Y1175‑p, INSR (rat): Y1186‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-2 increase
IGF-1 no change compared to control

Y1189-p - INSR (human)
Modsite: RDIYETDyYRKGGKG SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1189‑p, INSR iso2 (human): Y1177‑p, INSR (mouse): Y1179‑p, INSR (rat): Y1190‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-2 increase
IGF-1 no change compared to control

Y1190-p - INSR (human)
Modsite: DIYETDYyRKGGKGL SwissProt Entrez-Gene
Orthologous residues
INSR (human): Y1190‑p, INSR iso2 (human): Y1178‑p, INSR (mouse): Y1180‑p, INSR (rat): Y1191‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-2 increase
IGF-1 no change compared to control

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, AKT1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-2 increase
IGF-1 increase slight increase

T203-p - ERK1 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-1 no change compared to control
IGF-2 no change compared to control

Y205-p - ERK1 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-1 no change compared to control
IGF-2 no change compared to control

T183-p - ERK2 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-1 no change compared to control
IGF-2 no change compared to control

Y185-p - ERK2 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
IGF-1 no change compared to control
IGF-2 no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.